• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Oct. 26 Glenmark Pharmaceuticals Ltd has signed a 10-year marketing and distribution agreement with MeyerZall Laboratories.

The deal formalised through Glenmark Pharmaceuticals South Africa, helps expand the company’s product portfolio in the topical dermatology segment.

The agreement covers therapeutic areas such as psoriasis, fungal infections of the skin and inflammation.

As a result, products like Linotar Gel 1, Covarex and Athru-Derm, all with unique patented delivery systems, come into the Glenmark fold.

The company’s existing range of derma products includes Synalar, Synalar-C, Synalar-N and Naseptin.

In December 2005, Glenmark Pharmaceuticals Ltd acquired Bouwer Bartlett Pty Ltd, a South African sales and marketing company, through its wholly-owned Swiss subsidiary.

Currently, its pharmaceutical business unit produces, markets, sells and distributes a range of ethical dermatological products including brands like Synalar and Naseptin, the company told the Bombay Stock Exchange. Glenmark is one of the leading players in the Indian dermatology segment with Candid B featuring among the top 300 pharmaceutical products in the country, it added.

More Stories on : Alliances & Joint Ventures | Channels and Franchises | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Suven, US varsity in pact

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line